Aspirin

Introduction Overview

Generic Name

aspirin

Brand Name

Ecotrin

Dosage Form

oral

Drug Class

Platelet aggregation inhibitors, Salicylates

Pharmacokinetics

Absorption: Aspirin is rapidly absorbed from the gastrointestinal tract, primarily in the stomach and upper small intestine. The rate of absorption may vary depending on the formulation; immediate-release aspirin is absorbed more quickly compared to enteric-coated forms, which delay dissolution until reaching the more alkaline environment of the small intestine. Food intake can slow the absorption rate but does not significantly affect the extent of absorption. Aspirin is hydrolyzed to salicylic acid during and after absorption, which is responsible for most of its pharmacological effects.

Distribution: Following absorption, aspirin and its metabolite salicylic acid are widely distributed throughout body tissues and fluids, including the synovial fluid and cerebrospinal fluid. Approximately 80-90% of salicylic acid binds reversibly to plasma proteins, predominantly albumin. The volume of distribution varies with dose; at low doses, it is approximately 0.1 to 0.2 L/kg but increases at higher doses due to saturation of protein binding sites, leading to higher free drug concentrations.

Metabolism: Aspirin undergoes rapid hydrolysis by esterases in the gut mucosa, plasma, and liver to yield salicylic acid. Salicylic acid is further metabolized primarily in the liver through conjugation with glycine forming salicyluric acid and conjugation with glucuronic acid to form phenolic and acyl glucuronides. The rate of metabolism is dose-dependent; at higher doses, the conjugation pathways become saturated, and oxidative metabolism to gentisic acid via cytochrome P450 enzymes contributes significantly.

Elimination: The elimination half-life of aspirin itself is very short, less than 20 minutes, due to rapid hydrolysis. Salicylic acid has a dose-dependent half-life, generally ranging from 2 to 3 hours at low doses, extending up to 15 to 30 hours with high doses due to saturation of metabolic pathways. Salicylates are primarily excreted by the kidneys through glomerular filtration and tubular secretion. Urinary pH significantly affects elimination; alkaline urine increases ionization and excretion of salicylates, while acidic urine promotes reabsorption, which is clinically relevant in cases of overdose when urinary alkalinization is used to enhance clearance.

Dosage Forms

Available Dosage Forms: Ecotrin is available primarily as an oral enteric-coated tablet formulated to reduce gastric irritation. The common dosages include 81 mg (low-dose or baby aspirin), 325 mg, and 500 mg tablets. Chewable tablets are also available for cases requiring rapid absorption, especially in acute situations. Specific formulations are designed to optimize therapeutic use, including over-the-counter options for pain relief and prescription-strength tablets for cardiovascular prophylaxis.

Dosages for Adults and Adolescents: For cardiovascular protection, low-dose Ecotrin 81 mg once daily is commonly used. For analgesic and antipyretic effects, 325 mg to 650 mg every 4 to 6 hours as needed, not exceeding 4 grams per day, is typical. In prevention of stroke or myocardial infarction, the range is 50-325 mg daily, depending on individual risk and physician guidance. Chewable tablets are preferred during acute coronary syndromes for rapid onset.

Specific Patient Populations: In pediatric patients, aspirin is generally not recommended due to the risk of Reye’s syndrome, especially during viral illnesses. In elderly patients, the lowest effective dose is advised due to increased risk of gastrointestinal bleeding. Dose adjustments may be required in patients with renal or hepatic impairment, considering altered pharmacokinetics and increased bleeding risk. Pregnancy use is generally contraindicated, especially in the third trimester, due to potential fetal and maternal hemorrhagic complications. Breastfeeding is also not recommended during therapy with aspirin due to risk of exposure and side effects in the infant.

Mechanism Of Action

Aspirin (acetylsalicylic acid) exerts its primary pharmacological effect through irreversible inhibition of the cyclooxygenase (COX) enzymes COX-1 and COX-2. It acetylates a serine residue in the active site of these enzymes, leading to suppression of prostaglandin and thromboxane synthesis. This acetylation prevents the conversion of arachidonic acid into prostaglandin H2, a precursor for various prostanoids involved in inflammation, pain, fever, and platelet aggregation.

On a cellular level, aspirin’s inhibition of COX-1 in platelets results in decreased formation of thromboxane A2 (TXA2), a potent promoter of platelet aggregation and vasoconstriction. Because platelets are anucleate and cannot resynthesize COX enzymes, the effect of aspirin on platelet function lasts for the lifespan of the platelet (7-10 days), providing its unique antiplatelet activity valuable in cardiovascular protection.

Aspirin also reduces the production of prostaglandins involved in sensitizing nerve endings to pain and mediators of fever and inflammation by inhibiting COX-2 expressed during inflammatory responses. Compared to other NSAIDs, aspirin has a distinctive irreversible mechanism, whereas many NSAIDs are reversible COX inhibitors. This contributes to its differentiated clinical use, particularly in secondary prevention of atherothrombotic events.

Extensive studies have demonstrated aspirin’s efficacy in preventing myocardial infarction, stroke, and vascular death by reducing platelet aggregation. Research also explores aspirin’s potential in cancer prevention, particularly colorectal cancer, through mechanisms involving modulation of inflammation and cellular proliferation. Its mechanism remains a cornerstone in cardiovascular pharmacology and therapeutics.

Pharmacological Actions

Irreversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2) leading to decreased prostaglandins and thromboxanes.
Antiplatelet effect via suppression of thromboxane A2 synthesis, reducing platelet aggregation.
Anti-inflammatory effects through reduced synthesis of pro-inflammatory prostaglandins.
Analgesic action by inhibiting prostaglandin-mediated sensitization of pain receptors.
Antipyretic activity via lowering of hypothalamic set point for body temperature through prostaglandin modulation.
Gastrointestinal mucosal protection compromised due to COX-1 inhibition leading to reduced cytoprotective prostaglandins.
Potential modulation of cancer-related pathways, including inhibition of platelet activation and chronic inflammation related to tumorigenesis.
Distinct irreversible COX inhibition differentiating it from other reversible NSAIDs.
Prolongs bleeding time by impairing platelet aggregation, useful in thrombosis prevention.
Modulates vascular tone through effects on endothelial prostacyclin and platelet thromboxane balance.

Therapeutic Or Clinical Uses

Prevention of cardiovascular events including myocardial infarction and ischemic stroke.
Management of acute coronary syndrome as an adjunct to reperfusion therapy.
Secondary prevention of transient ischemic attacks and stroke.
Treatment of mild to moderate pain such as headache, musculoskeletal pain, and menstrual cramps.
Reduction of fever associated with infections or other causes.
Anti-inflammatory therapy in certain conditions such as rheumatoid arthritis or other inflammatory disorders.
Prophylaxis of arterial thromboembolism in patients with prosthetic heart valves or atrial fibrillation when anticoagulants are contraindicated.
Reduction of risk of colorectal cancer and other malignancies in selected high-risk populations.
Use in peripheral arterial disease for prevention of occlusive events.
Management of Kawasaki disease in pediatric patients to reduce coronary artery complications.
Reduction of pain, inflammation, and swelling in osteoarthritis in adults.
Adjunct therapy in antiphospholipid syndrome to prevent thrombotic events.
Reduction of risk of preeclampsia in pregnant women at risk, under careful supervision.

Side Or Adverse Effects

Gastrointestinal irritation, including dyspepsia, heartburn, and nausea.
Increased risk of gastrointestinal ulcers, bleeding, and perforation.
Allergic reactions ranging from mild rash to anaphylaxis, particularly in aspirin-sensitive individuals.
Tinnitus and hearing loss associated with salicylate toxicity.
Reye's syndrome in children and adolescents following viral infections.
Prolonged bleeding time leading to increased risk of hemorrhage during surgery or trauma.
Dizziness, confusion, and rarely neurotoxicity at high doses or overdose.
Renal impairment or worsening of preexisting kidney disease due to altered renal prostaglandin synthesis.
Hypersensitivity pneumonitis or asthma exacerbation in susceptible patients.
Potential for hepatotoxicity in rare cases with high-dose chronic use.
Bronchospasm or allergic reactions in patients with aspirin-exacerbated respiratory disease (AERD).
Anemia secondary to blood loss or hemolysis.
Fluid retention and peripheral edema in susceptible individuals.
Skin reactions including Stevens-Johnson syndrome (rare).

Precautions

Use cautiously in patients with history of peptic ulcers or gastrointestinal bleeding.
Avoid in children or teenagers with viral illnesses to prevent Reye's syndrome.
Careful monitoring in patients with asthma or nasal polyps due to risk of hypersensitivity reactions.
Use with caution in patients with renal or hepatic impairment; assess risk-benefit ratio.
Avoid use during late pregnancy due to risk of bleeding complications in mother and fetus.
Monitor for signs of bleeding, especially in patients on anticoagulants or other platelet inhibitors.
Use the lowest effective dose for the shortest duration necessary to minimize adverse effects.
Patients with bleeding disorders or coagulopathies require precautions and specialist consultation.
Avoid concurrent use with other NSAIDs or salicylates without medical supervision.
Caution in elderly patients due to increased susceptibility to adverse reactions, especially GI bleeding.
Advise patients to take with food or use enteric-coated formulations to reduce gastric irritation.
Inform patients about signs of toxicity such as tinnitus, dizziness, and confusion.
Evaluate interactions with other medications, including antidepressants and blood thinners.
Correct patient adherence and education regarding avoidance of alcohol to reduce bleeding risk.

Warnings

Risk of Reye's syndrome in children and teenagers, particularly during viral infections.
Potential for serious gastrointestinal bleeding, ulceration, and perforation which can be fatal.
Hypersensitivity reactions including anaphylaxis and bronchospasm in aspirin-sensitive individuals.
Avoid use in the third trimester of pregnancy due to risk of fetal and maternal bleeding.
May increase risk of bleeding, particularly in patients receiving anticoagulant therapy.
Do not discontinue abruptly in patients using aspirin for cardiovascular protection without medical advice.
Use caution in patients with asthma as it may induce bronchospasm.
Risk of salicylate toxicity with overdose or chronic high-dose use, requiring prompt medical intervention.
Not recommended for use during breastfeeding due to risk of infant exposure.
Avoid sudden cessation to prevent risk of thrombotic events in cardiovascular patients.
Monitor for signs of hepatic or renal impairment during prolonged therapy.
Use with caution in patients with gout or metabolic acidosis.
Risk of bleeding may be exacerbated when combined with alcohol or other anticoagulants.
Consult healthcare provider before surgery as aspirin can increase bleeding risk.

Contraindication

Known hypersensitivity or allergy to aspirin or other salicylates.
Active or recent history of gastrointestinal bleeding or peptic ulcer disease.
Bleeding disorders such as hemophilia or thrombocytopenia.
History of aspirin-induced asthma or severe allergic reactions to NSAIDs.
Children or teenagers with viral infections (flu, chickenpox) due to risk of Reye's syndrome.
Third trimester of pregnancy due to risk of fetal complications and bleeding.
Severe liver or kidney impairment where aspirin metabolism or excretion is severely compromised.
Patients undergoing certain surgeries or invasive procedures without discontinuation as advised.
Concomitant use with other salicylates or anticoagulants without medical supervision.
Patients with nasal polyps or chronic urticaria who have experienced aspirin hypersensitivity.
Known bleeding disorders or predisposition to bleeding complications.
Severe uncontrolled hypertension or congestive heart failure with fluid overload.
Patients with a history of severe gastrointestinal mucosal damage.
Do not use in breastfeeding mothers to avoid risk to the infant.

Drug Interactions

Increased bleeding risk when combined with anticoagulants such as warfarin, heparin, and direct oral anticoagulants.
Concomitant use with other NSAIDs such as ibuprofen may reduce aspirin’s cardioprotective effect and increase gastrointestinal toxicity.
Interaction with selective serotonin reuptake inhibitors (SSRIs) leading to increased risk of bleeding.
Concurrent use with corticosteroids increases risk of gastrointestinal ulceration and bleeding.
Interaction with antihypertensives like ACE inhibitors and diuretics may reduce antihypertensive efficacy.
Combination with methotrexate may increase methotrexate toxicity due to displacement from plasma proteins.
Probenecid may decrease renal clearance of salicylates, increasing plasma levels.
Alcohol consumption potentiates gastrointestinal irritation and bleeding risk.
May interfere with urine diagnostic tests due to false positive or negative results.
Co-administration with valproic acid increases risk of bleeding and hematologic toxicity.
Antidiabetic drugs may have altered effects due to aspirin’s influence on glucose metabolism.
Salicylates can displace other highly protein-bound drugs, altering their free plasma concentration.
Potential interference with platelet function tests and coagulation assays.
Concurrent use with other salicylates results in additive toxicity and increased side effect profile.

Preparations Of The Drug

Enteric-coated tablets available in 81 mg, 325 mg, and 500 mg strengths designed to reduce gastric irritation.
Chewable aspirin tablets for faster absorption, typically in 81 mg and 325 mg doses, used in acute coronary syndromes.
Buffered aspirin formulations combining aspirin with antacids to mitigate gastrointestinal side effects.
Controlled-release and extended-release aspirin formulations for sustained plasma levels and prolonged effect.
Combination products with other analgesics or antipyretics such as acetaminophen (though not marketed as Ecotrin).
Low-dose aspirin preparations specifically marketed for cardiovascular prophylaxis.
Generic aspirin oral tablets in immediate-release and enteric-coated forms.
Aspirin powders and granules for oral suspension, though less commonly used in clinical practice.
Topical or rectal forms are generally not applicable for Ecotrin brand but exist for aspirin in other contexts.
Specialized aspirin formulations with additional agents such as caffeine or salicylate salts for enhanced efficacy.
Liquid aspirin formulations for pediatric or patients with swallowing difficulties, not typical of Ecotrin but relevant in class.